Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study

被引：0

作者：

Giovannoni, Gavin ^{[1
]}

Comi, Giancarlo ^{[2
]}

Cook, Stuart ^{[3
]}

Rammohan, Kottil ^{[4
]}

Rieckmann, Peter ^{[5
]}

Soelberg-Sorensen, Per ^{[6
]}

Vermersch, Patrick ^{[7
]}

Hamlett, Anthony ^{[8
]}

Scaramozza, Matthew ^{[9
]}

Lachenal, Nathalie ^{[10
]}

机构：

[1] Barts & London Queen Marys Sch Med & Dent, Blizard Inst, London, England

[2] Inst Expt Neurol, Milan, Italy

[3] Univ Med & Dent New Jersey, Newark, NJ 07103 USA

[4] Ohio State Univ, Miami, FL USA

[5] Dept Neurol, Bamberg, Germany

[6] Danish MS Ctr, Copenhagen, Denmark

[7] Univ Lille, Lille, France

[8] EMD Serono Inc, Rockland, NY USA

[9] EMD Serono Inc, Rockland, MA USA

[10] Merck Serono, Geneva, Switzerland

来源：

NEUROLOGY | 2013年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P07119

引用

下载

页数：2

共 50 条

[31] Age-related efficacy of cladribine tablets in patients with relapsing-remitting ms in the clarity extension study
Freedman, M.
Pardo, G.
De Stefano, N.
Aldridge, J.
Hyvert, Y.
Galazka, A.
Lemieux, C.
Giovannoni, G.
White, N.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 257 - 258
[32] Safety and tolerability of BG-12 in patients with relapsing-remitting multiple sclerosis: results from the phase 3 CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis) study
Havrdova, E.
Phillips, J. T.
Fox, R. J.
Miller, D.
Kita, M.
Hutchinson, M.
Raghupathi, K.
Yuan, H.
Novas, M.
Sweetser, M. T.
Viglietta, V.
Dawson, K. T.
JOURNAL OF NEUROLOGY, 2012, 259 : S105 - S105
[33] Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis
Giovannoni, G.
Comi, G.
Cook, S.
Rammohan, K.
Rieckmann, P.
Sorensen, P. S.
Vermersch, P.
Chang, P.
Hamlett, A.
Musch, B.
Fevr, T.
Greenberg, S.
MULTIPLE SCLEROSIS, 2009, 15 (09): : S136 - S137
[34] Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
Hauser, Stephen
Li, David
Calabresi, Peter
O'Connor, Paul
Bar-Or, Amit
Barkhof, Frederik
Sauter, Annette
Leppert, David
Masterman, Donna
Tinbergen, Jeroen
Kappos, Ludwig
NEUROLOGY, 2013, 80
[35] The Safety and Efficacy of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis in the SELECTION Extension Study: Primary Results
Giovannoni, Gavin
Gold, Ralf
Selmaj, Krzysztof
Havrdova, Eva
Montalban, Xavier
Radue, Ernst-Wilhelm
Stefoski, Dusan
McNeill, Manjit
Rana, Jitesh
Elkins, Jacob
O'Neill, Gilmore
NEUROLOGY, 2013, 80
[36] Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial
Saida T.
Kira J.-I.
Kishida S.
Yamamura T.
Ohtsuka N.
Ling Y.
Torii S.
Lucas N.
Kuesters G.
Steiner D.
Tibung J.T.
Neurology and Therapy, 2017, 6 (1) : 39 - 55
[37] Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
Sorensen, Per S.
Lisby, Steen
Grove, Richard
Derosier, Frederick
Shackelford, Steve
Havrdova, Eva
Drulovic, Jelena
Filippi, Massimo
NEUROLOGY, 2014, 82 (07) : 573 - 581
[38] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
Oh, Jiwon
O'Connor, Paul W.
CNS DRUGS, 2013, 27 (08) : 591 - 609
[39] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
Jiwon Oh
Paul W. O’Connor
CNS Drugs, 2013, 27 : 591 - 609
[40] Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study
Comi, Giancarlo
Cook, Stuart
Rammohan, Kottil
Sorensen, Per Soelberg
Vermersch, Patrick
Adeniji, Abidemi K.
Dangond, Fernando
Giovannoni, Gavin
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11 : 1 - 11

← 1 2 3 4 5 →